



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/109,082 07/02/98 MELKI

J 2121-140P

002292 HM22/0718

BIRCH STEWART KOLASCH & BIRCH

P O BOX 747

FALLS CHURCH VA 22040-0747

EXAMINER

HAYES, R

ART UNIT

PAPER NUMBER

1647

DATE MAILED:

07/18/00

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner of Patents and Trademarks**



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/109,082			

EXAMINER	
ART UNIT	PAPER NUMBER
	12

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

The communication filed on **05/10/00** is not fully responsive to the communication mailed **04/10/00** because 37 CFR 1.821 (a)(2)(c-d) states that each sequence disclosed must appear separately in the "Sequence listing" and in the text of the description and claims (i.e., where first mentioned in the specification). See MPEP 2431. For example, page 20 of the specification discloses nucleotide and amino acid sequences for Figures 10-12. Moreover, SEQ ID NO:21 of Figure 10 is an amino acid sequence and not a genomic nucleotide sequence, as currently disclosed, which alternatively appears to represent the amino acid sequence depicted in Figure 12. Additionally, Figure 11 lists a nucleotide sequence of 637 nucleotide residues, whereas SEQ ID NO:22 of Figure 11 is a genomic sequence of 3271 nucleotide residues. It is also unclear whether the sequences depicted in Figure 13 are represented by a SEQ ID NO. Clarification is required. Please recheck that all sequences are mentioned at least once in the specification and are directed toward the correct sequence. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the response appears to be bona fide, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid **abandonment** under 37 CFR 1.821(g). **EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).**

Any inquiry concerning this communication should be directed to Examiner **Robert C. Hayes**, Art Unit **1647**, whose telephone number is **703-305-3132**

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

*RC*  
Robert C. Hayes, Ph.D.  
July 17, 2000

*Gary L. Kunz*  
GARY L. KUNZ  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER